Maribavir for Cytomegalovirus Treatment in the Real World—Not a Silver Bullet

Monica Fung(University of California, San Francisco), Sarah B. Doernberg(Johns Hopkins University), Natasha Spottiswoode(University of California, San Francisco), Catherine DeVoe(University of California, San Francisco)
Open Forum Infectious Diseases
December 28, 2022
10.1093/ofid/ofac686
Cited by 16

Related Papers

COVID-19 in Immunocompromised Hosts: What We Know So Far
|Clinical Infectious Diseases|2020|568
Integrating host response and unbiased microbe detection for lower respiratory tract infection diagnosis in critically ill adults
|Proceedings of the National Academy of Sciences|2018|434
Epidemiology and Risk Factors for Clostridium difficile Infection in Children
|The Pediatric Infectious Disease Journal|2011|168
Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19
|JAMA|2021|166
Randomized Trial Evaluating Clinical Impact of RAPid IDentification and Susceptibility Testing for Gram-negative Bacteremia: RAPIDS-GN
|Clinical Infectious Diseases|2020|133